Basile Edward M 4

What Happened

Edward M. Basile, a director of TransMedics Group, Inc. (TMDX), was granted 2,922 restricted stock units (RSUs) on May 20, 2026. The Form 4 records the acquisition at $0.00 (code A), indicating an equity award rather than an open‑market purchase; total reported acquisition value is $0.00. The filing was made on May 22, 2026.

Key Details

• Transaction date: 2026-05-20; Form 4 filed: 2026-05-22 (appears timely — within the usual two‑business‑day window).
• Transaction type/code: Grant/Award (A).
• Shares/units granted: 2,922 RSUs reported at $0.00 per unit (aggregate $0).
• Shares owned after transaction: Not specified in the information provided.
• Footnote: F1 — Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the issuer's common stock.

Context

RSUs are compensation awards that convert to actual shares if and when vesting conditions are met; they do not require an immediate cash purchase by the insider. Such grants are common for directors and executives as part of compensation packages and do not, by themselves, indicate a direct buy or sell decision in the market.